Comprehensive Review of Female Hair Loss

1. Introduction and Epidemiology

Female androgenetic alopecia (FPHL), commonly referred to as female pattern hair loss, is the most prevalent form of non-scarring alopecia in women, affecting up to 50% of women throughout their lifetime [1]. Unlike its male counterpart, the presentation and underlying mechanisms of FPHL differ significantly, with more diffuse thinning patterns characterised by retention of the frontal hairline. The psychological impact of hair loss extends beyond cosmetic concerns, substantially affecting quality of life, self-esteem, and psychological well-being in affected patients [2]. Despite its prevalence and significant patient burden, treatment options remain limited, with only topical minoxidil receiving FDA approval specifically for women [3].

2. Pathophysiology of Female Hair Loss

2.1 Genetic and Hormonal Mechanisms

The pathophysiology of female androgenetic alopecia is multifactorial and complex, involving interplay between genetic predisposition, hormonal factors, and environmental influences [1]. While dihydrotestosterone (DHT) is recognised as a crucial mediator in male pattern hair loss, its exact role in female pattern hair loss remains unclear, with evidence suggesting that women with FPHL may develop hair loss without significantly elevated androgen levels [3]. This fundamental difference underscores the distinct biological mechanisms underlying FPHL compared to male androgenetic alopecia.

Genetic studies have identified numerous susceptibility loci associated with hair loss patterns. Sex-specific genetic analysis in a Korean population revealed novel loci, including TSNARE1 (involved in vesicle transport), FZD1 (a key regulator of the Wnt signalling pathway), and GJC1 (a gap junction protein), suggesting that oestrogen-mediated signalling pathways may differentially influence follicular cycling in women [4]. These findings indicate that female pattern hair loss represents an etiologically distinct condition from male androgenetic alopecia, requiring separate therapeutic approaches.

2.2 Hair Follicle Miniaturisation and Cycle Dysregulation

The hallmark of androgenetic alopecia in both sexes is progressive miniaturisation of hair follicles, characterised by shortened anagen (growth) phases, lengthened telogen (resting) phases, and progressive reduction in hair shaft diameter [3]. In female pattern hair loss, this process results in thinner, shorter hairs in characteristic distribution patterns, typically beginning with widening of the central hair parting and diffuse thinning over the crown and mid-frontal areas [5].

At the molecular level, the Wnt/beta-catenin signalling pathway emerges as a critical regulator of hair follicle cycling and miniaturisation. Dysregulation of this pathway, combined with impaired signalling between the dermal papilla and hair follicle cells, drives the miniaturisation process [6]. Growth factors, including epidermal growth factor (EGF), insulin-like growth factor (IGF-1), and vascular endothelial growth factor (VEGF), all play essential roles in hair follicle development and regeneration, and their dysregulation contributes to the pathogenesis of pattern hair loss.

2.3 Associated Systemic and Metabolic Factors

Emerging evidence reveals important associations between female androgenetic alopecia and systemic metabolic conditions. A substantial proportion of women with FPHL (approximately 59.4%) demonstrate metabolic syndrome, suggesting shared pathogenic mechanisms involving insulin resistance, oxidative stress, and inflammatory dysregulation [7]. Furthermore, polycystic ovary syndrome (PCOS), characterized by hormonal imbalances and elevated androgen production, commonly presents with concurrent hair loss, indicating hormonal links in FPHL pathophysiology [8].

Sleep patterns and circadian rhythm disruptions also emerge as novel pathogenic factors. Evening chronotype has been identified as an independent risk factor for androgenetic alopecia, with mechanistic studies demonstrating altered clock gene expression (particularly PER3) and circadian rhythm abnormalities in severe cases, suggesting that temporal metabolic dysregulation contributes to hair loss [9]. Additionally, the scalp microbiome has been implicated, with significant correlations demonstrated between specific bacterial colonisation patterns (elevated Staphylococcus and Cutibacterium species) and female androgenetic alopecia [10].

3. Clinical Diagnosis and Assessment

3.1 Clinical Classification and Diagnostic Methods

Female pattern hair loss is typically assessed using the Ludwig scale, which categorises severity from I (mild) through III (severe) based on the degree of central hair loss [1]. Clinical diagnosis requires careful history taking, physical examination, and assessment of hair loss patterns. Importantly, dermoscopy (trichoscopy) has emerged as a valuable non-invasive diagnostic tool providing superior sensitivity to trichograms in early disease stages, allowing visualisation of hair miniaturisation and follicular changes characteristic of androgenetic alopecia [11].

3.2 Diagnostic Biomarkers and Laboratory Assessment

Comprehensive patient evaluation should include screening for systemic conditions and hormonal abnormalities associated with hair loss, including thyroid function, iron status, and androgenic markers [12]. In women presenting with signs of hyperandrogenism (such as hirsutism, acne, or menstrual irregularities), more extensive hormonal investigation may be warranted to exclude androgen-secreting tumors or congenital adrenal hyperplasia [13]. The identification of metabolic comorbidities (dyslipidemia, metabolic syndrome) should prompt preventive cardioascular interventions [14].

4. Established Treatment Options

4.1 Topical Minoxidil

Topical minoxidil at 2% concentration twice daily remains the only FDA-approved pharmacological treatment for female pattern hair loss  [5]. The mechanism of action involves vasodilation that increases oxygenated and growth factor-enriched blood flow to hair follicles, while also prolonging the anagen phase and promoting hair follicle proliferation [5]. Clinical efficacy demonstrates significant improvements in hair density and reduction in hair shedding, with approximately 40% of women showing meaningful hair regrowth [15]. However, approximately 60% of patients demonstrate limited or no response to monotherapy, necessitating combination approaches.

Recent evidence supports the efficacy of topical minoxidil in combination therapy paradigms. Combination of topical minoxidil 3% with 17?-oestradiol demonstrated superior efficacy compared to minoxidil alone in postmenopausal women, suggesting that hormonal modulation enhances response [16]. Similarly, minoxidil combined with carboxytherapy showed statistically significant increases in hair diameter and density compared to minoxidil monotherapy at both 3 and 6 months [17].

4.2 Oral and Topical Finasteride

Although oral finasteride (5 mg daily) is not FDA-approved for women due to theoretical teratogenic risks, mounting clinical evidence supports its efficacy in female pattern hair loss, particularly in postmenopausal women and those with documented hyperandrogenism [18]. Comparative studies demonstrate that oral finasteride 5 mg daily provides comparable or superior outcomes to topical minoxidil 5%, with documented improvements persisting beyond 6 months [19]. Lower-dose finasteride (2.5 mg daily) shows efficacy particularly in younger women, though plateau effects occur after 3 months [20].

Topical finasteride represents an important advance, offering localized 5?-reductase inhibition with minimal systemic absorption, thereby reducing concerns about systemic side effects [21]. Head-to-head comparisons demonstrate that topical finasteride 1% achieves efficacy comparable to minoxidil 5%, with superior trichoscopic improvements including reduction in yellow dots and peripilar signs [21]. Combination therapy with topical finasteride and minoxidil demonstrates synergistic benefits, representing a rational multimodal approach [22].

4.3 Antiandrogen Therapy

Oral antiandrogens including spironolactone, cyproterone acetate, and emerging agents like bicalutamide offer alternatives for women with documented hyperandrogenism or those intolerant of other therapies [3]. Spironolactone at 100 mg daily shows additive effects when combined with topical minoxidil, though menstrual irregularities occur in approximately 37.5% of users, representing a significant tolerability concern [23]. Bicalutamide, a selective androgen receptor antagonist, demonstrates favourable safety and tolerability profiles with minimal systemic effects on reproductive hormones, showing promise as an emerging option particularly for women with concurrent hyperandrogenic features [24].

Notably, the safety profile of antiandrogen therapy warrants careful consideration in women with a history of gynaecological malignancies, although available evidence suggests spironolactone maintains safety even in high-risk populations [25]. Topical antiandrogens may offer advantages with potentially fewer systemic effects when used in combination with minoxidil [3].

4.4 Low-Dose Oral Minoxidil

Emerging evidence supports efficacy of low-dose oral minoxidil (LDOM) in female pattern hair loss, with typical dosing of 0.625-2.5 mg daily showing benefits comparable to or exceeding topical formulations in some patients [12]. A retrospective series of female patients treated with LDOM monotherapy reported hair regrowth in 36% of patients with no discontinuations due to efficacy failure, and facial hypertrichosis in 16% [26]. Consensus recommendations from an international expert panel suggest starting doses of 0.625-1.25 mg daily for women, with maximum daily doses of 2.5 mg, and baseline blood pressure monitoring is essential [27].

4.5 Combination Therapy Paradigm

Contemporary evidence strongly supports the superiority of combination therapy over monotherapy for female pattern hair loss  [22]. A systematic review comparing hormonal and non-hormonal therapies demonstrated that combinations involving non-hormonal methods (such as PLLA microthread therapy combined with topical minoxidil 2%) significantly increased hair density from baseline 114±27/cm² to 143±25/cm², substantially greater than minoxidil monotherapy [28]. The multimodal case report of female androgenetic alopecia employed combination therapy incorporating minoxidil, baicapil, capilia longa, chelated zinc, saw palmetto, and microinfusion with KGF, copper peptides, and trichoxidil, achieving significant hair density improvement and stabilisation [29].

5. Emerging Therapeutic Approaches

5.1 Novel Pharmacological Agents

Emerging pharmacological therapies targeting androgens and follicular regeneration pathways show considerable promise. Clascoterone (Winlevi) represents the first topical androgen receptor antagonist approved by the FDA for acne, with preliminary evidence supporting efficacy in androgenetic alopecia through selective local androgen receptor blockade without systemic absorption [30]. Pyrilutamide, another selective androgen receptor modulator under investigation, demonstrates hair growth promotion in preclinical and early clinical studies with potentially superior safety profiles compared to systemic antiandrogens [31].

JAK inhibitors, while established for alopecia areata therapy, are being investigated for potential benefits in androgenetic alopecia through mechanisms involving immune modulation and follicular regeneration signalling [32]. Small molecule inhibitors targeting the Wnt/?-catenin pathway show therapeutic potential, with compounds such as PTD-DBM demonstrating the ability to activate this critical hair follicle regeneration pathway [33].

5.2 Platelet-Rich Plasma and Regenerative Therapies

Platelet-rich plasma (PRP) therapy has emerged as a prominent regenerative approach for androgenetic alopecia, with mechanism of action involving delivery of growth factors including EGF, IGF-1, VEGF, and PDGF to hair follicles [6]. A comparative study of minoxidil 2% monotherapy versus combination with PRP demonstrated significant increases in hair density (31.21-34.92 hairs/cm²) in both groups without significant between-group differences, suggesting that PRP offers benefit, particularly in patients with minoxidil adherence issues [34].

Mesenchymal stem cell (MSC)-derived exosomes represent a frontier in regenerative therapy for androgenetic alopecia, operating through cell-free mechanisms that avoid cellular immunity concerns while delivering bioactive microRNAs, growth factors, and proteins [35]. Single-cell RNA sequencing studies reveal that exosomes derived from amniotic mesenchymal stem cells alleviate DHT-induced mitochondrial dysfunction and dermal papilla damage through Wnt/?-catenin signalling pathway activation, resetting the hair follicle stem cell niche to favour regeneration [36]. Clinical evidence demonstrates substantial hair density improvements (9.5-35 hairs/cm²) with high patient satisfaction and no serious adverse events across multiple exosome sources [37].

Adipose-derived stem cell (ADSC) therapy and their secretome products show therapeutic potential for hair restoration, though current evidence remains primarily at level 3b (case series) due to heterogeneous study designs and small sample sizes [38]. ADSC-conditioned medium demonstrates intradermal efficacy through enhanced hair follicle density, increased anagen hair rate, and improved scalp parameters including increased dermal thickness [39].

5.3 Device-Based and Physical Modalities

Low-level laser therapy (LLLT) using red light wavelengths (630-660 nm) has gained prominence as a non-invasive, bioregulatory approach to hair loss management [40]. The photobiomodulation mechanism involves stimulation of mitochondrial oxidative phosphorylation through cytochrome c oxidase interaction, enhancing ATP production and cellular energy availability [41]. Clinical studies demonstrate LLLT effectiveness in promoting hair growth and reducing inflammation, with red-light irradiation (650 nm) significantly increasing hair follicle numbers and ATP levels in skin tissue [41]. The combination of LLLT with scalp microneedling using clobetasol propionate showed statistically significant improvement in clinical parameters after three monthly treatment sessions [42].

Microneedling, also termed collagen induction therapy, generates controlled dermal trauma that induces regenerative signaling and growth factor release, with combined application with topical finasteride and minoxidil demonstrating synergistic benefits [43]. Fractional radiofrequency and other mechanical stimulation modalities activate fibroblast proliferation and collagen remodeling, complementing pharmacological interventions [44].

5.4 Nutritional and Botanical Approaches

Emerging evidence supports roles for specific micronutrients and phytochemicals in supporting hair follicle health. Sulforaphane-rich broccoli sprout extract demonstrated dose-dependent proliferative and migratory effects on keratinocytes, dermal fibroblasts, and dermal papilla cells, with in vivo efficacy surpassing minoxidil in testosterone-induced androgenetic alopecia models [45]. The mechanism involved upregulation of hepatic and dermal DHT-metabolizing enzymes (Akr1c21, Dhrs9) and Wnt/ beta catenin pathway activation, suggesting dual actions through androgen metabolism modulation [45].

Rosemary extract contains bioactive compounds including 1,8-cineole, rosmarinic acid, and carnosic acid that demonstrate multiple beneficial properties: enhanced microcapillary circulation, 5 alpha reductase inhibition, and antibacterial, anti-inflammatory, and antioxidant effects supporting hair follicle renewal [46]. Vitamin D supplementation combined with topical minoxidil demonstrates superior efficacy compared to monotherapy in female pattern hair loss, with combination treatment showing greatest improvements in both hair density and vitamin D status [47].

6. The Hype Around Copper Peptides and Thymosin Beta-4: Critical Examination of Emerging Claims

6.1 Copper Peptides (GHK-Cu): Evidence and Reality

Copper peptides, particularly the tripeptide glycine-histidine-lysine (GHK) complexed with copper (GHK-Cu), have garnered considerable popular attention in hair loss circles and cosmetic dermatology, often presented as miracle compounds for hair regeneration. The biological basis for interest is legitimate: GHK-Cu demonstrates multiple beneficial properties including enhanced collagen and elastin synthesis, promotion of angiogenesis, stimulation of fibroblast migration, and anti-inflammatory/antioxidant effects [48].

However, the scientific evidence for hair growth promotion specifically remains surprisingly limited. While GHK has been shown to reset genes of diseased cells toward healthier states and improve wound healing in experimental models, direct clinical evidence demonstrating efficacy in androgenetic alopecia remains scarce  [48]. The multimodal case report featuring copper peptide microinfusion alongside numerous other active ingredients makes it impossible to isolate the specific contribution of copper peptides to the observed hair growth  [29].

Copper peptides incorporated into supramolecular nanostructures demonstrate enhanced bioactivity compared to native GHK in wound healing models, with improved proteolytic stability and efficacy [49]. The Food-derived tripeptide-copper self-healing hydrogel demonstrated promotion of neovascularisation and hair follicle regeneration in infected wound models, though this represents wound healing contexts rather than androgenetic alopecia treatment [50].

Critical Assessment:

While copper peptides possess theoretical merit and demonstrate wound healing properties, robust clinical randomized controlled trials specifically demonstrating efficacy in female androgenetic alopecia remain absent. The enthusiasm for these compounds substantially exceeds current evidence-based support. They may have supportive roles in comprehensive regimens, but should not be presented as primary or alternative treatments to established therapies.

6.2 Thymosin Beta-4: Biological Promise and Clinical Reality Gap

Thymosin beta-4 (T beta 4), a 43 kDa peptide found in all body fluids and cells, has received considerable attention in regenerative medicine and hair loss circles. The biological activities are indeed extensive: T beta 4 functions as a G-actin sequestering protein regulating cell motility, suppresses inflammatory cytokine production, reduces apoptosis, promotes angiogenesis, stimulates nerve outgrowth, and increases cellular stemness [51].

The hair regeneration research with thymosin is genuinely intriguing. Animal studies demonstrate that T beta 4 promotes hair follicle regeneration and growth [52], and the protein was identified as upregulated when endothelial cells were cultured on Matrigel basement membrane matrix, itself a hair-inductive substrate [52]. A cockroach-derived thymosin analog (Pa-THYs) demonstrated efficacy in wound healing models through stimulation of dermal tissue regeneration, angiogenesis, and collagen deposition, with activation of growth factor expression [53].

Thymosin beta-4 shows promise in animal models of hair loss and wound healing, with documented effects on hair follicle regeneration through stimulation of dermal tissue regeneration and growth factor expression. Additionally, LL-37 peptide (human cathelicidin) has been demonstrated to activate adipose-derived stem cells, resulting in enhanced secretion of thymosin beta-4, VEGF, monocyte chemoattractant protein-1, and stromal cell-derived factor-1, collectively promoting robust hair growth in vivo [54].

Critical Assessment:

Despite genuine biological plausibility and positive animal model data, clinical evidence for thymosin beta-4 efficacy in human androgenetic alopecia is virtually non-existent. No published randomised controlled trials in humans demonstrate efficacy in female pattern hair loss. The enthusiasm for thymosin beta-4 in hair loss treatment substantially exceeds available human clinical data. While it may have theoretical merit and warrants further investigation, it cannot currently be recommended as an evidence-based treatment for female androgenetic alopecia. The gap between exciting preclinical biology and clinical efficacy represents a crucial cautionary tale about translational research.

6.3 Why the Hype? Understanding the Evidence-to-Promotion Gap

Several factors explain the substantial marketing emphasis on copper peptides and thymosin beta-4 despite limited clinical evidence:

1. Legitimate Biological Plausibility: Both compounds possess genuine molecular mechanisms relevant to tissue regeneration and wound healing, creating superficially convincing rationales [48], [51].
2. Preclinical to Clinical Translation Failures: The frequent disconnect between promising animal model studies and disappointing human clinical trials represents a well-recognised phenomenon in translational research  [33].
3. Regulatory Gaps: These peptides operate in regulatory gray zones—not FDA-approved drugs but marketed as cosmeceuticals or supplements, allowing broader claims with minimal clinical evidence requirements.
4. Commercial Interests: The cosmetic dermatology and supplement industries benefit from novel, “cutting-edge” compounds that command premium pricing.
5. Patient Desperation: Hair loss patients often pursue aggressive investigation of emerging treatments, creating market demand for unproven therapies.

7. Current Treatment Recommendations and Personalisation

7.1 Evidence-Based Management Algorithms

Contemporary evidence supports first-line therapy with topical minoxidil 2% (twice daily) or oral minoxidil (0.625-2.5 mg daily) as the most established single agents with demonstrated efficacy in female pattern hair loss [12]. For women with signs of hyperandrogenism or those intolerant of minoxidil, oral spironolactone 50-100 mg daily or topical finasteride represents a reasonable alternative, though informed consent regarding potential side effects is essential  [3].

Combination therapy incorporating multiple mechanisms demonstrates superior outcomes compared to monotherapy. Rational combinations include: (1) minoxidil + topical or oral finasteride, (2) minoxidil + antiandrogens (spironolactone or bicalutamide), (3) topical minoxidil + topical oestradiol (for postmenopausal women), or (4) pharmacological therapy + regenerative approaches (PRP, microneedling, LLLT) [32].

Treatment duration requirements demand patient counselling that a minimum of 6-12 months of continuous therapy is necessary to assess efficacy, with continued maintenance required to prevent relapse [12]. Patient factors, including age, signs of hyperandrogenism, fertility desires, cardiovascular risk factors, and access to medications, should guide therapy selection [3].

7.2 Multimodal and Adjunctive Strategies

For patients with inadequate response to dual-agent pharmacotherapy, addition of device-based modalities (LLLT, microneedling) or regenerative approaches (PRP, exosomes) may enhance outcomes  [32]. Integration of nutritional support addressing micronutrient deficiencies (iron, vitamin D, zinc) and botanical adjuncts (rosemary extract, broccoli sprouts) provides supportive care [45], [46]. Psychosocial support addressing the substantial psychological impact of hair loss, including cosmetic camouflage techniques, scalp micropigmentation, and wigs, remains an important element of comprehensive care [55].

8. Future Directions and Precision Medicine

The future of androgenetic alopecia treatment lies in personalised, genotype-informed approaches that account for individual genetic susceptibility and therapeutic responsiveness. SNP association analysis has identified eight specific genetic variants predicting variable treatment responses [56], with potential for development of predictive algorithms guiding therapy selection. Integration of artificial intelligence-driven diagnostics and phenotyping may enable early identification and preventive intervention strategies  [30].

Hair follicle neogenesis and regenerative engineering represent frontier approaches with potential to achieve true restoration rather than symptom management  [33]. Tissue engineering approaches combining scaffold materials, growth factors, and stem cell products may eventually enable recreation of functional hair-bearing skin. Gene therapy and PROTAC technologies (Proteolysis Targeting Chimeras) offer future possibilities for targeted intervention in androgenetic alopecia pathophysiology  [30].

Conclusion

Female androgenetic alopecia represents a prevalent, multifactorial condition with complex pathophysiology distinct from male pattern hair loss. Established therapies including topical minoxidil and topical/oral finasteride remain the foundation of evidence-based management, with mounting support for combination approaches addressing multiple pathogenic mechanisms. While emerging regenerative therapies including platelet-rich plasma, mesenchymal stem cell-derived exosomes, and device-based modalities show genuine promise, they should complement rather than replace established treatments pending completion of rigorous clinical trials.

The enthusiasm for copper peptides and thymosin beta-4 substantially exceeds current clinical evidence, representing important reminders about the evidence-to-marketing gap in translational research. Future progress lies in personalised approaches incorporating genetic profiling, multimodal therapy optimisation, and innovative regenerative strategies that address the underlying mechanisms of follicular miniaturisation. Clinicians should maintain evidence-based practice while remaining vigilant for emerging therapies meeting rigorous efficacy and safety standards.

Disclaimer: This article is for informational purposes only and does not replace professional medical advice.

References:

[1] B. Z. Maudina et al., “Androgenic Alopecia: A Comprehensive Literature Review of Epidemiology, Pathophysiology, Diagnosis, and Management,” JURNAL BIOLOGI TROPIS, Oct. 2025, doi: 10.29303/jbt.v25i4.10182.

[2] C.-Y. Ho et al., “Female Pattern Hair Loss: An Overview with Focus on the Genetics,” Genes, Jun. 2023, doi: 10.3390/genes14071326.

[3] M. M. Ong, M. Avram, A. McMichael, A. Tosti, and S. Lipner, “Anti-androgen therapy for the treatment of female pattern hair loss: a clinical review of current and emerging therapies.,” Journal of American Academy of Dermatology, May 2025, doi: 10.1016/j.jaad.2025.04.074.

[4] J. Lee, J.-E. Choi, J. Ha, Y. Kim, C. Lee, and K.-W. Hong, “Genetic Differences between Male and Female Pattern Hair Loss in a Korean Population,” Life, Jul. 2024, doi: 10.3390/life14080939.

[5] M. Stradczuk et al., “How to treat androgenetic alopecia – the most common form of hair loss. A review,” Journal of Education, Health and Sport, Jun. 2024, doi: 10.12775/jehs.2024.73.51729.

[6] R. Abdin, Y. Zhang, and J. Jimenez, “Treatment of Androgenetic Alopecia Using PRP to Target Dysregulated Mechanisms and Pathways,” Frontiers in Medicine, Mar. 2022, doi: 10.3389/fmed.2022.843127.

[7] A. Naeem, S. Fasih, R. Mukhtar, M. Anwar, M. Qamar, and S. Khalid, “FREQUENCY OF METABOLIC SYNDROME IN PATIENTS WITH FEMALE PATTERN HAIR LOSS,” Pakistan journal of physiology, Mar. 2025, doi: 10.69656/pjp.v21i1.1767.

[8] N. Elsarah, M. A. Elsohafy, A. Zayed, and A. Fawzi, “Study of the Prevalence of Different Causes of Hair Loss among Females with Polycystic Ovary Syndrome in Delta Area-Egypt,” The Egyptian Journal of Hospital Medicine, Oct. 2024, doi: 10.21608/ejhm.2024.392956.

[9] Q. Wu, M.-H. Li, Y. Xiong, Y. Li, Y.-W. Zheng, and L. Liu, “Association between sleep patterns, circadian rhythms, and hair loss in young adults,” Chronobiology International, Aug. 2025, doi: 10.1080/07420528.2025.2547938.

[10] J. Dhillon, I. Putra, and N. Jusuf, “The relationship between microbiome and female androgenetic alopecia,” Bali Medical Journal, Jan. 2025, doi: 10.15562/bmj.v14i1.5560.

[11] P. Kakizaki, V. B. Rocha, C. Machado, and N. Valente, “Diagnostic Performance of the Trichogram Compared to Histopathology of Scalp Biopsy in Horizontal Sections in Female Androgenetic Alopecia: A Retrospective Study.,” Skin Appendage Disorders, Jan. 2026, doi: 10.1159/000550541.

[12] L. Iyengar and J. Li, “Male and female pattern hair loss,” Australian Prescriber, Jun. 2025, doi: 10.18773/austprescr.2025.020.

[13] M. F. F. Hernández et al., “Male Pattern Androgenetic Alopecia Linked to an Adrenal Tumor: A Case Report,” Skin Appendage Disorders, Feb. 2025, doi: 10.1159/000543887.

[14] S. K. A. Kumaraswamy, D. Nayak, and N. B. Lingaiah, “From Hairline to Lipid Line: Prevalence and Spectrum of Dyslipidemia in Patients with Androgenetic Alopecia – A Hospital-Based Study,” Journal of Skin and Stem Cell, Dec. 2025, doi: 10.5812/jssc-165789.

[15] P. M. Ramos, D. F. Melo, H. Radwanski, R. F. C. D. Almeida, and H. A. Miot, “Female-pattern hair loss: therapeutic update,” Anais Brasileiros de Dermatologia, Mar. 2023, doi: 10.1016/j.abd.2022.09.006.

[16] S. Choe, S. Lee, J. Choi, and W.-S. Lee, “Therapeutic Efficacy of a Combination Therapy of Topical 17?-Estradiol and Topical Minoxidil on Female Pattern Hair Loss: A Noncomparative, Retrospective Evaluation,” Annals of Dermatology, May 2017, doi: 10.5021/ad.2017.29.3.276.

[17] F. Alzahraa, R. M. Khedr, M. Khaled, G. Selim, H. Fathy, and Khedr, “Combination of Minoxidil 5% with Carboxytherapy versus Minoxidil 5% Alone in Treatment of Female Pattern Hair Loss,” The Egyptian Journal of Hospital Medicine, Jul. 2023, doi: 10.21608/ejhm.2023.309012.

[18] N. N. Nobari et al., “A systematic review of clinical trials using single or combination therapy of oral or topical finasteride for women in reproductive age and postmenopausal women with hormonal and nonhormonal androgenetic alopecia.,” Advances in Clinical and Experimental Medicine, Mar. 2023, doi: 10.17219/acem/157990.

[19] E. H. E. Morsy, A. S. A. Toto, and E. M. Hassan, “Oral Finasteride (5 mg and 2 mg) versus Topical Minoxidil 5% in Female Pattern Hair Loss,” Clinical Dermatology Review, Jan. 2025, doi: 10.4103/cdr.cdr_87_24.

[20] Y.-Y. Won, B.-L. Lew, and W. Sim, “Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg/day in women with female pattern hair loss,” Dermatologic Therapy, Mar. 2018, doi: 10.1111/dth.12588.

[21] N. M. A. Sayed, E. H. E. Morsy, T. Hussein, and E. M. Hassan, “Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment,” Dermatology Practical & Conceptual, Jan. 2025, doi: 10.5826/dpc.1501a4698.

[22] S. Deoghare and N. Sadick, “Combination therapy in female pattern hair loss,” Journal of Cosmetic & Laser Therapy, May 2023, doi: 10.1080/14764172.2023.2222942.

[23] P. Werachattawatchai, S. Khunkhet, S. Harnchoowong, and C. Lertphanichkul, “Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot study,” International Journal of Women’’s Dermatology, Sep. 2025, doi: 10.1097/JW9.0000000000000227.

[24] R. D. M. Carvalho et al., “Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know,” Journal of Cosmetic Dermatology, Jan. 2022, doi: 10.1111/jocd.14773.

[25] S. Morteza, S. Jafari, K. Heidemeyer, R. Hunger, and P. A. D. Viragh, “Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies,” Journal of Clinical Medicine, May 2024, doi: 10.3390/jcm13113052.

[26] R. Imhof, B. K. Villalpando, and R. Torgerson, “Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring,” JAAD International, Aug. 2023, doi: 10.1016/j.jdin.2023.08.002.

[27] A. K. Gupta et al., “Low-dose oral minoxidil (LDOM) and topical minoxidil: consensus recommendations for managing male and female pattern hair loss in hair transplant patients using a modified Delphi process,” Expert Opinion on Pharmacotherapy, Feb. 2026, doi: 10.1080/14656566.2026.2642216.

[28] O. Alsuwailem et al., “Efficacy Of Hormonal Therapy Vs Non-Hormonal Therapy in Female Pattern Hair Loss (FPHL): A Systematic Review,” International Journal of Medicine in Developing Countries, 2026, doi: 10.24911/ijmdc.51-1764746615.

[29] L. Junqueira, L. M. B. Pessoa, and T. C. D. Souza, “Integrated Therapeutic Approaches in the Treatment of Female Androgenetic Alopecia: A Case Report,” Brazilian Journal of Hair Health, Feb. 2025, doi: 10.62742/2965-7911.2025.2.bjhh22.

[30] K. Niewola, M. Ró?a?ska, K. Rozenberg, J. Stryjecka, and J. ?wiercz, “ADVANCEMENTS IN TREATMENT STRATEGIES FOR ANDROGENETIC ALOPECIA: NOVEL THERAPIES AND FUTURE PERSPECTIVES,” International Journal of Innovative Technologies in Social Science, Dec. 2025, doi: 10.31435/ijitss.4(48).2025.4221.

[31] Z. Czy?ewicz, W. Zamirska, N. Hornig, A. Cieplak, A. Ko?odziej, and M. Czy?ewicz, “Androgenetic alopecia – a literature review,” Journal of Education, Health and Sport, Jun. 2025, doi: 10.12775/jehs.2025.82.60223.

[32] S. Kumaresan, D. Palaniappan, N. Manickam, S. G. Vellaisamy, and K. Gopalan, “A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies,” IP Indian Journal of Clinical and Experimental Dermatology, Dec. 2025, doi: 10.18231/j.ijced.13629.1765276898.

[33] A. Mehta et al., “Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies,” Cells, May 2025, doi: 10.3390/cells14110779.

[34] A. Agarwal and V. Mendiratta, “Comparative Efficacy of Topical Minoxidil Alone Against Combination of Topical Minoxidil and Platelet Rich Plasma in Women with Female Pattern Hair Loss—A Pilot, Open Randomised Trial,” Indian Journal of Dermatology, Jan. 2023, doi: 10.4103/ijd.ijd_461_22.

[35] F. A. Penha, G. A. Penha, and H. M. C. Acerbi, “A Comprehensive Literature Review: The Potential of Exosomes in Hair Growth and Transplantation,” International Society of Hair Restoration Surgery, May 2025, doi: 10.33589/35.3.73.

[36] X.-Y. Wang et al., “Single?Cell RNA Sequencing Highlights a Contribution of Human Amniotic Mesenchymal Stem Cells?Derived Exosomes to Androgenetic Alopecia,” The FASEB Journal, Jul. 2025, doi: 10.1096/fj.202500853R.

[37] M. A. A. Ameer et al., “Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources,” Clinical, Cosmetic and Investigational Dermatology, Sep. 2025, doi: 10.2147/CCID.S543451.

[38] A. Ortega-Cuartiella, “Therapeutic Potential of Adipose-Derived Stem Cells and Their Secretome in Reversible Alopecias: A Systematic Review,” International Journal of Trichology, Sep. 2023, doi: 10.4103/ijt.ijt_3_21.

[39] K. Narita, H. Fukuoka, T. Sekiyama, H. Suga, and K. Harii, “Sequential Scalp Assessment in Hair Regeneration Therapy Using an Adipose-Derived Stem Cell-Conditioned Medium.,” Dermatologic Surgery, Jun. 2020, doi: 10.1097/DSS.0000000000002128.

[40] A. Aabedi and D. K. Agrawal, “Convergent Regenerative Strategies in PM&R for Musculoskeletal and Hair Restoration: Integration of PRP, Exosomes, and Physical Modalities,” Archives of Internal Medicine Research, Feb. 2026, doi: 10.26502/aimr.0234.

[41] S. Xu et al., “FLIM Reveals Red Light-Induced Changes in Murine Hair Follicles,” Biosensors, Apr. 2026, doi: 10.3390/bios16050232.

[42] M. Sukarnadi and S. Hidayat, “Efficacy of Low Level Laser Therapy Combined with Scalp Microneedling using Clobetasol Propionate 0,05% Solution for the Management of Androgenetic Alopecia,” Journal of Medical and Health Studies, Nov. 2023, doi: 10.32996/jmhs.2023.4.6.2.

[43] W. Pawlik, A. Nowotarska, G. B?aszczy?ski, P. Nojek, M. Zimonczyk, and M. Zawó?, “Hair loss therapies: a review and comparison of traditional and modern treatment methods,” Journal of Education, Health and Sport, Nov. 2024, doi: 10.12775/jehs.2024.75.56191.

[44] D. Liu, Q. Xu, X. Meng, X. Liu, and J. Liu, “Status of research on the development and regeneration of hair follicles,” International Journal of Medical Sciences, Jan. 2024, doi: 10.7150/ijms.88508.

[45] L. Subedi et al., “Sulforaphane-Rich Broccoli Sprout Extract Promotes Hair Regrowth in an Androgenetic Alopecia Mouse Model via Enhanced Dihydrotestosterone Metabolism,” International Journal of Molecular Sciences, Aug. 2025, doi: 10.3390/ijms26157467.

[46] A. Sharma, V. Reddy, B. Kumar, and A. Tiwari, “Phytotherapeutic Potential of Rosemary in Hair Growth and Hair Fall Prevention: Mechanisms, Efficacy, and Future Perspectives,” Current Cosmetic Science, Nov. 2025, doi: 10.2174/0126667797404811251017073853.

[47] M. Azeem, R. Naseem, S. Amir, B. Rahat, and B. Aurangzeb, “Comparison of Treatment with Oral Vitamin D Alone, Topical Minoxidil or Combination of Both in Patients of Female Pattern Hairloss,” Research Journal for Social Affairs, Jan. 2025, doi: 10.71317/rjsa.003.01.0060.

[48] L. Pickart, J. M. Vasquez-Soltero, and A. Margolina, “GHK and DNA: Resetting the Human Genome to Health,” BioMed Research International, Sep. 2014, doi: 10.1155/2014/151479.

[49] V. I. B. Castro, A. R. Araújo, R. L. Reis, I. Pashkuleva, and R. Pires, “Nanoengineered Self-Assembling Peptides with Increased Proteolytic Stability Promote Wound Healing,” ACS Applied Materials and Interfaces, Feb. 2025, doi: 10.1021/acsami.4c18221.

[50] H. Chen et al., “Food-Derived Tripeptide–Copper Self-Healing Hydrogel for Infected Wound Healing,” Biomaterials Research, Jan. 2025, doi: 10.34133/bmr.0139.

[51] J. Gao et al., “Thymosin ?4 and actin: binding modes, biological functions and clinical applications.,” Current protein and peptide science, Dec. 2022, doi: 10.2174/1389203724666221201093500.

[52] H. Kleinman, K. Kim, and H. Kang, “Matrigel uses in cell biology and for the identification of thymosin ?4, a mediator of tissue regeneration,” Applied Biological Chemistry, Sep. 2018, doi: 10.1007/s13765-018-0400-6.

[53] J. Jing et al., “Cloning, Expression and Effects of P. americana Thymosin on Wound Healing,” International Journal of Molecular Sciences, Oct. 2019, doi: 10.3390/ijms20194932.

[54] Y. Yang, H. Choi, M. Seon, D. Cho, and S. Bang, “LL-37 stimulates the functions of adipose-derived stromal/stem cells via early growth response 1 and the MAPK pathway,” Stem cell research & therapeutics, Apr. 2016, doi: 10.1186/s13287-016-0313-4.

[55] C. P, B. B. H. Baraka, B. V. Rao, C. S. Karadi, S. V. Gowda, and R. Kumar, “Androgenetic Alopecia: update on Etiology, Pathophysiology, Diagnosis and Treatment,” International Journal of Pharmaceutical Sciences and Drug Research, Mar. 2024, doi: 10.25004/ijpsdr.2024.160220.

[56] M. P. Francès, L. Vila-Vecilla, V. Russo, H. C. Polonini, and G. T. D. Souza, “Utilising SNP Association Analysis as a Prospective Approach for Personalising Androgenetic Alopecia Treatment,” Dermatologic Therapy, Mar. 2024, doi: 10.1007/s13555-024-01142-y.